Latest:
Dr Fankuchen on Practice-Informing Updates to the Thoracic Oncology Treatment Paradigm
Olivia Fankuchen, MD, MS, highlights molecular targets, trial data, and real-world experiences that have immediate implications for the lung cancer field.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
William M. Sikov, MD
Latest:
Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer
William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.
Kathryn C. Arbour, MD
Kathryn C. Arbour, MD, is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York.
Latest:
Preliminary Safety and Antitumor Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with KRAS G12D NonSmall Cell Lung Cancer (NSCLC) from a Phase 1 Study in Advanced Solid Tumors
Dr. Kathryn C. Arbour presents preliminary findings from a Phase 1 study showing that zoldonrasib, a selective RAS(ON) G12D inhibitor, demonstrates encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12D–mutant non–small cell lung cancer.
Margaret T. Kasner, MD
Latest:
Practice Pearls for Treatment of Secondary AML in the Community Setting
Panelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.
Helen Moon, MD
Latest:
Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases
Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.
Stefan Maksimovic, MD
Latest:
Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCC
Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.
Priyadarshini Pathak, MBBS
Latest:
Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS
Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.
Joanne Kurtzberg, MD
Latest:
Dr. Kurtzberg on Long-term OS for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
Joanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.
David J. Benjamin, MD
David J. Benjamin, MD, is a medical oncologist at Hoag Family Cancer Institute.
Latest:
Dr Benjamin on Using Real-World Data to Bridge Knowledge Gaps in Urothelial Cancer Care
David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.
American Oncology Network
Latest:
American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care Gap
American Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.